Thalomid (thalidomide) — United Healthcare
Pediatric Central Nervous System Cancer (Medulloblastoma)
Initial criteria
- Diagnosis of pediatric medulloblastoma
- AND
- Disease is recurrent or progressive
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Thalomid therapy
Approval duration
12 months